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ABSTRACT
Background    Of all parotid gland tumors, only on-
cocytoma has been reported to appear isointense to the 
parotid gland, namely vanishing, on fat-saturated T2 
and T1 postcontrast gadolinium-enhanced magnetic res-
onance imaging (MRI). The purpose of this study was 
to evaluate vanishing of parotid tumors on conventional 
MRI with and/or without postcontrast gadolinium-en-
hancement and on diffusion weighted imaging (DWI). 
Methods    In 8 of 51 patients, ten parotid gland tumors 
had homogeneously enhanced lesions and were retro-
spectively analysed. Comparisons of signal intensity 
between those parotid tumors and parotid glands and 
evaluations of vanishing were performed on T1-weight-
ed imaging (T1WI), T2-weighted imaging (T2WI), 
fat-suppressed T2WI (FS-T2WI), postcontrast gadolini-
um-enhanced T1WI (CE-T1WI) and fat-suppressed CE-
T1WI (FS-CE-T1WI), DWI as well as apparent diffu-
sion coefficient (ADC). 
Results    Ten parotid gland tumors consisted of five 
Warthin tumors, two pleomorphic adenomas, two parot-
id carcinomas (small cell carcinoma and adenoid cystic 
carcinoma) and one oncocytoma. All tumors showed 
hypointensity on T1WI and hyperintensity on DWI. 
Nine of ten tumors showed vanishing on the other MR 
sequences. All Warthin tumors showed vanishing on FS-
T2WI, FS-CE-T1WI and the ADC map. One oncocyto-
ma showed vanishing on FS-T2WI and the ADC map 
and hyperintensity on FS-CE-T1WI. All pleomorphic 
adenomas showed vanishing on T2WI and CE-T1WI. 
One adenoid cystic carcinoma showed vanishing only on 
CE-T1WI. 
Conclusion    Vanishing of parotid tumors can be ob-
served not only on FS-T2WI and FS-CE-T1WI but also 
on T2WI, CE-T1WI and ADC mapping.
Key words    magnetic resonance imaging; oncocytoma; 
parotid tumor; vanishing; Warthin tumor
Computed tomography (CT), magnetic resonance im-
aging (MRI) and ultrasonography are commonly used 
to evaluate parotid gland lesions. Several parotid gland 
lesions, such as pleomorphic adenoma, are occasionally 
invisible on contrast-enhanced CT; the conspicuity of 
these lesions can be reduced due to a combination of the 
high density of the parotid gland and weak enhancement 
of the lesion.1 Meanwhile, of all parotid gland tumors, 
only oncocytoma has been reported to appear isointense 
to the parotid gland, namely vanishing on fat-saturated 
T2 and T1 postcontrast gadolinium-enhanced MRI.2 
However, there have been no reports evaluating whether 
any other parotid tumors show vanishing on various MR 
sequences. The vanishing of parotid tumors on MRI re-
quires tumor homogeneity and isointensity to the normal 
parotid gland. Furthermore, the contrast of signal inten-
sity between parotid tumors and normal parotid glands 
can be altered due to the extent of tumor contrast en-
hancement on postcontrast gadolinium-enhanced MRI 
and due to the extent of fat suppression of parotid glands 
with physiological fat deposition on fat-suppressed MRI. 
Generally, large tumors can be inhomogeneous due to 
necrosis, degeneration or hemorrhage. Therefore, tumor 
vanishing is considered to be a feature of small tumors 
on MRI. The purpose of this study was to evaluate van-
ishing of parotid tumors on conventional MRI with and/
or without postcontrast gadolinium-enhancement and on 
diffusion weighted imaging (DWI).
MATERIALS AND METHODS
Patients
Between April 2010 and May 2016, MRI examinations 
were performed on 51 consecutive patients suspected of 
parotid tumors in our hospital. Of the 51 patients, thir-
ty-nine patients underwent gadolinium-enhanced MRI 
and DWI. Of the 39 patients, only eight patients who had 
34
E. Matsusue et al.
homogeneously enhanced lesions (3 females, 5 males; 
median age, 56 years; range, 42–75 years; number of 
lesions, 10 parotid gland tumors) were included in the 
present study and retrospectively analysed. Histopatho-
logical diagnoses were made on the basis of findings in 
specimens obtained at surgical resection (Table 1). This 
retrospective study was approved by the institutional re-
view board of our institution, and the informed consent 
requirement was waived.
MRI
MR examinations were performed within two months 
before surgery in all patients. MRI was performed us-
ing a 1.5T MRI system (Excite HD; GE Healthcare, 
Milwaukee, WI) with head and neck array coils. The 
parameters for T1 and T2 weighted imaging (T1WI, 
T2WI) were as follows. For the axial pre and postcon-
trast gadolinium-enhanced T1-weighted spin-echo se-
quence, the parameters were repetition time, 500 msec; 
echo time, 8 msec; matrix, 256 × 256; section thickness, 
5 mm; intersection gap, 1 mm; field of view, 22 cm; 
and two signals averaged. For the axial T2-weighted 
fast spin-echo sequence, the parameters were repetition 
time, 3500 msec; echo time, 90msec; matrix, 256 × 256; 
section thickness, 5 mm; intersection gap, 1mm; field 
of view, 22 cm; and two signals averaged. For the axial 
fat-suppressed T2-weighted fast spin-echo sequence, the 
parameters were repetition time, 4300 msec; echo time, 
90 msec; matrix, 256 × 256; section thickness, 5 mm; 
intersection gap, 1mm; field of view, 22 cm; and two 
signals averaged. For the postcontrast gadolinium-en-
hanced 3D fat-suppressed T1-weighted multiphase 
spoiled gradient recalled sequence, the parameters were 
repetition time, 5msec; echo time, 2.5 msec; matrix, 256 
× 256; effective section thickness, 2 mm; field of view, 
22 cm; and three signals averaged. The parameters for 
diffusion-weighted imaging were as follows for the axial 
spin-echo single-shot echo-planar sequence: repetition 
time, 4300 msec; echo time, 80msec; matrix, 128 × 128; 
section thickness, 5-mm, intersection gap, 1-mm; field 
of view, 22 cm; and two signals averaged. Sensitizing 
diffusion gradients were applied sequentially in the x, 
y, and z directions with b values of 0 and 800 sec/mm2. 
Apparent diffusion coefficient (ADC) maps were also 
generated. 
Evaluations of MR images
One author (E.M., 20 years of experience in head and 
neck MR imaging) evaluated the MR images obtained 
by T1WI, T2WI, fat-suppressed T2WI (FS-T2WI), post-
contrast gadolinium-enhanced T1WI (CE-T1WI) and 
fat-suppressed CE-T1WI (FS-CE-T1WI), DWI and ADC 
mapping. The approximate tumor volume was calculated 
from the product of tumor length, width, and depth and 
the multiplication factor π/6. The signal intensity (SI) in 
each sequence was visually judged as ‘low’ (hypointen-
sity) when the SI of the tumor was lower than that of the 
parotid tissue, ‘iso’ (isointensity) when the SI was equal 
to that of the parotid tissue, and ‘high’ (hyperintensity) 
when the SI was brighter than that of the parotid tissue. 
RESULTS
Table 1 shows the MRI features of the ten parotid gland 
tumors, which comprised five Warthin tumors, one on-
cocytoma, two pleomorphic adenomas and two parotid 
carcinomas (small cell carcinoma and adenoid cystic 
carcinoma) in eight patients. One patient had three 
Warthin tumors. The average volume of all tumors was 
Table 1. MRI features of parotid tumors
Patient Age (years) Volume Size ADC value 
No. /Sex Diagnosis (cm3) (cm) T1WI T2WI CET1WI FST2WI FSCET1WI DWI ADC (× 10-3 mm2/s)
1 61/M Warthin tumor    0.9 1.2 Low Low Low Iso Iso High Iso 0.84
2 52/M Warthin tumor    5.4 2.2 Low Low Low Iso Iso High Iso 0.88
3 56/M Warthin tumor    2.5 1.7 Low Low Low Iso Iso High Iso 0.96
3 56/M Warthin tumor    10.7 2.8 Low Low Low Iso Iso High Iso 1.13
3 56/M Warthin tumor    7.6 2.5 Low Low Low Iso Iso High Iso 1.05
4 75/F Oncocytoma 0.9 1.2 Low Low Low Iso High High Iso 1.09
5 53/F Pleomorphic adenoma 0.2 0.7 Low Iso Iso High High High High 1.51
6 42/M Pleomorphic adenoma 1.1 1.3 Low Iso Iso High High High High 1.41
7 59/M Small cell carcinoma 4.1 2 Low Low Low High High High Low 0.73
8 61/F Adenoid cystic carcinoma 0.3 0.9 Low Low Iso High High High High 1.29
ADC, apparent diffusion coefficient; CE-T1WI, postcontrast gadolinium-enhanced T1-weighted imaging; DWI, diffusion-weighted im-
aging; F, female; FS-CE-T1WI, fat-suppressed CE-T1WI; FS-T2WI, fat-suppressed T2-weighted imaging; M, male; MRI, magnetic reso-
nance imaging; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging.
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Fig. 1. Warthin tumor of the right parotid gland in a 56-year-old 
man (case 3). 
A: T1WI shows a well-defined hypointense mass in the right pa-
rotid gland.
B: FS-T2WI shows the mass is isointense (arrow) compared to the 
parotid gland. 
C: FS-CE-T1WI shows the mass is isointense (arrow) compared to 
the parotid gland. 
D: ADC mapping shows the mass is isointense (arrow) compared 
to the parotid gland. The ADC value of the mass was 0.84 × 10-3 
mm2/sec.
E: High-power view showing proliferation of the glandular epithe-
lium with oncocytic cytoplasm (left) and lymphoid stroma (right) (hematoxylin-eosin, scale bar = 25 μm).
ADC, apparent diffusion coefficient; FS-CE-T1WI, fat-suppressed postcontrast gadolinium-enhanced T1-weighted imaging; FS-T2WI, 
fat-suppressed T2-weighted imaging; T1WI, T1-weighted imaging.
Fig. 2. Oncocytoma of the right parotid gland in a 75-year-old 
woman (case 4).
A: T1WI shows a well-defined hypointense mass in the right pa-
rotid gland.
B: FS-T2WI shows the mass is isointense (arrow) compared to the 
parotid gland. 
C: FS-CE-T1WI shows the mass is hyperintense compared to the 
parotid gland. 
D: ADC mapping shows the mass is isointense (arrow) compared 
to the parotid gland. The ADC value of the mass was 1.09 × 10-3 
mm2/sec.
E: High-power view showing oncocytic cells with granular and 
abundant cytoplasm and thin fibrovascular stroma (hematoxylin-eosin, scale bar = 25 μm).
ADC, apparent diffusion coefficient; FS-CE-T1WI, fat-suppressed postcontrast gadolinium-enhanced T1-weighted imaging; FS-T2WI, 
fat-suppressed T2-weighted imaging; T1WI, T1-weighted imaging.
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Fig. 3. Pleomorphic adenoma of the right parotid gland in a 
42-year-old man (case 6). 
A: T1WI shows a well-defined hypointense mass in the right pa-
rotid gland.
B: T2WI shows the mass is isointense (arrow) compared to the 
parotid gland. 
C: CE-T1WI shows the mass is isointense (arrow) compared to the 
parotid gland. 
D: FS-T2WI shows the mass is hyperintense compared to the pa-
rotid gland.
E: High-power view showing the epithelial component forming 
sheets (lower left) and a mesenchymal myxoid component (upper 
right) (hematoxylin-eosin, scale bar = 25 μm).
ADC, apparent diffusion coefficient; FS-CE-T1WI, fat-suppressed postcontrast gadolinium-enhanced T1-weighted imaging; FS-T2WI, 
fat-suppressed T2-weighted imaging; T1WI, T1-weighted imaging.
Fig. 4. Adenoid cystic carcinoma of the right parotid gland in a 
61-year-old woman (Case 8).  
A: T1WI shows a well-defined hypointense mass in the right pa-
rotid gland.
B: T2WI shows the mass is hypointense compared to the parotid 
gland. 
C: CE-T1WI shows the mass is isointense (arrow) compared to the 
parotid gland. 
D: FS-T2WI shows the mass is hyperintense compared to the pa-
rotid gland.
E: High-power view showing nests of biphasic cells with cylindro-
matous microcystic spaces filled with hyaline or mucoid material 
(hematoxylin-eosin, scale bar = 25 μm).
ADC, Apparent diffusion coefficient; FS-CE-T1WI, fat-suppressed postcontrast gadolinium-enhanced T1-weighted imaging; FS-T2WI, 
fat-suppressed T2-weighted imaging; T1WI, T1-weighted imaging.
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3.4 cm3 (range, 0.2–10.7 cm3). The average diameter of 
all tumors was 1.7 cm (range, 0.7–2.5 cm). All tumors 
showed ‘low’ on T1WI and ‘high’ on DWI. Nine of ten 
tumors showed ‘iso’ on any other MR sequences. All 
Warthin tumors showed ‘iso’ on FS-T2WI, FS-CE-
T1WI and ADC map (Fig. 1). One oncocytoma showed 
‘iso’ on FS-T2WI and ADC mapping and ‘high’ on FS-
CE-T1WI (Fig. 2). All pleomorphic adenomas showed 
‘iso’ on T2WI and CE-T1WI (Fig. 3). One adenoid cystic 
carcinoma showed ‘iso’ only on CE-T1WI (Fig. 4), al-
though one small cell carcinoma showed no ‘iso’ on any 
MR sequence. 
DISCUSSION
It is generally accepted that the average size of parotid 
tumors at diagnosis is approximately 3 centimeters.3 Pa-
tel et al. reported that eight of nine oncocytomas showed 
vanishing on both FS-T2WI and FS-CE-T1WI. The av-
erage cross-sectional diameter of the eight oncocytomas 
was 2.6 ± 0.7 cm (range, 1.3–3.3 cm).2 This diameter is 
consistent with the average size of parotid tumors. In 
this study, the average diameter of all ten tumors show-
ing homogeneous enhancement was 1.7 ± 0.7cm (range, 
0.7–2.5 cm), smaller than that of typical parotid tumors. 
Furthermore, in addition to homogeneous enhancement, 
nine of the ten tumors showed vanishing. Hence, van-
ishing parotid tumors are likely among homogeneous 
tumors of small to average size. 
 In the present study, both Warthin tumors and on-
cocytoma showed hypointensity both on T2WI and CE-
T1WI. Histologically, oncocytoma is composed of large 
epithelial cells with a characteristic bright eosinophilic 
granular cytoplasm, namely oncocytes. A thin fibro-
vascular stroma is also present.4 Warthin tumors are 
composed of epithelial and lymphoid components. The 
epithelium comprises two layers of cells: large oncocyt-
ic cells and smaller basal cells. Lymphoid components 
with varying degrees of reactivity and with germinal 
centers are typical.5 Therefore, both Warthin tumors 
and oncocytoma are hypercellular tumors with abun-
dant microvessels. Generally, the cellular components 
are recognized as hypointensity on T2WI. In addition, 
hypointensity on conventional CE-T1WI is usually seen 
in hypercellular tumors showing early enhancement and 
a high washout rate on dynamic images. These find-
ings are seen in benign tumors such as Warthin tumors 
and oncocytoma as well as in malignant tumors such 
as acinic cell carcinoma and malignant lymphoma.6–9 
In this study, both Warthin tumors and oncocytoma 
showed isointensity, namely vanishing, compared to the 
normal parotid glands on FS-T2WI. Furthermore, War-
thin tumors showed vanishing, but oncocytoma showed 
hyperintensity on FS-CE-T1WI. Patel et al. reported that 
eight cases with oncocytoma showed vanishing both 
on FS-T2WI and FS-CE-T1WI.2 The reason of the van-
ishing of oncocytoma in these MR sequences remains 
unclear. The hypointense tumor lesions on T2WI or CE-
T1WI might show vanishing, namely, isointensity to 
normal parotid glands with decreased signal intensity 
due to fat signal suppression on FS-T2WI or FS-CE-
T1WI. In the present study, both Warthin tumors and 
oncocytoma also showed vanishing on the ADC maps. 
This finding may be attributable to the high cellularity of 
these tumors, which show low ADC values nearly iden-
tical to those of the normal parotid gland. Interestingly, 
both oncocytoma and Warthin tumors show increased 
99mTcO4- uptake on single photon emission computed 
tomography (SPECT) and also can exhibit increased 
fluorodeoxyglucose (FDG) uptake on positron emission 
tomography (PET).10–12 Furthermore, Araki et al. report-
ed that synchronous oncocytoma and Warthin tumor in 
the ipsilateral parotid gland had very similar imaging on 
CT, MRI, US and 99mTcO4- pertechnetate scintigraphy.13 
Hence, these tumors might have pathophysiological sim-
ilarities as well as those histologic similarities.
 In this study, pleomorphic adenomas showed van-
ishing both on T2WI and CE-T1WI, hyperintensity both 
on FS-T2WI and FS-CE-T1WI, and hyperintensity on 
ADC mapping. Pleomorphic adenoma is histologically 
composed of epithelial and myoepithelial cells and has 
mesenchymal elements. The epithelial component shows 
a wide variety of cell types, and the mesenchymal com-
ponent is mucoid/myxoid, cartilaginous or hyalinised.14 
The T2-hyperintensity of pleomorphic adenomas, their 
increased ADC values, and their persistent enhancement 
after contrast administration are well-known as specific 
MRI findings consistent with fibromyxoid stroma.15–17 
Therefore, parotid tumors, including pleomorphic ade-
nomas, that show T2-hyperintensity and persistent en-
hancement can show isointense to normal parotid gland 
and might also show vanishing on T2WI or CE-TIWI. 
Furthermore, the tumor lesions were considered to 
show hyperintensity compared to parotid glands with 
decreased signal intensity due to their fat signal suppres-
sion on FS-T2WI or FS-CE-T1WI.
 Of the malignant tumors in the present study, only 
one adenoid cystic carcinoma with small size showed 
vanishing on CE-T1WI. Adenoid cystic carcinoma his-
tologically consists of epithelial and myoepithelial cells 
and has stroma with hyalinized, mucinous or myxoid 
features.18 The signal intensity of the adenoid cystic 
carcinoma might appear isointense to the parotid gland 
due to the tumor homogeneity associated with its small 
size and due to its persistent enhancement, which corre-
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sponds to a rich interstitial space, similar to pleomorphic 
adenoma.19 
 In the present study, all tumors showed hypointen-
sity on T1WI and hyperintensity on DWI, that is, they 
were depicted as conspicuous lesions on both T1WI and 
DWI. Meanwhile, vanishing of tumors was observed 
on T2WI, CE-T1WI, FS-T2WI, FS-CE-T1WI or ADC 
mapping. Therefore, isointense tumor lesions, compared 
to normal parotid glands, may be generally or partially 
overlooked on these sequences. Hence, MRI evaluation 
of parotid tumors should be performed initially by T1WI 
or DWI. Furthermore, considering the phenomenon of 
vanishing parotid tumors, careful evaluations of parotid 
glands on these sequences are necessary to avoid over-
looking incidental parotid tumors.
 Our study had several limitations. First, there was 
a problem with physiological fat depositions in parotid 
glands. Vanishing on MRI requires identical signals 
from parotid tumors and normal parotid glands. The 
extents of the physiological fat depositions of parotid 
glands varied in each case.20 Accordingly, our qualitative 
evaluations of vanishing were influenced not only by 
parotid tumor characteristics but also by the variations 
of the fat depositions of the parotid gland. Second, we 
included limited types of parotid tumors. Vanishing of 
parotid tumors was observed in oncocytoma, Warthin’s 
tumor, pleomorphic adenoma and adenoid cystic carci-
noma in this study. Therefore, vanishing may occur in 
parotid tumors of other histological types. A larger study 
of patients with parotid tumors is required. However, 
this is the first report to evaluate vanishing of parotid 
tumors in various MR sequences. 
 In conclusion, vanishing of parotid tumors was ob-
served in normal- to small-sized tumors on T2WI, CE-
T1WI, FS-T2WI, FS-CE-T1WI and ADC mapping. No 
vanishing of tumors was observed on T1WI and DWI. 
Therefore, MRI evaluation of parotid tumors should be 
performed initially by T1WI or DWI. Furthermore, van-
ishing of tumors on FS-T2WI and FS-CE-T1WI, which 
is considered characteristic of oncocytoma, can be ob-
served in Warthin tumors. 
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